Phase II study of maytansine in advanced sarcomas.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008453:Maytansine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010078:Oxazines / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*
D010078:Oxazines; D008453:Maytansine